Healing & Recovery

Pentadeca arginate

PDA · BPC-157 arginate · BPC-157 arginine salt · pentadecapeptide arginate

Arginine salt of BPC-157 (the same 15-aa gastric peptide), sold as a distinct SKU from BPC-157 acetate. Vendors claim better oral/gastric stability. There is no separate human PK package for the arginate salt — treat identity as BPC-157 with a different counterion. FDA Category 2 applies to the peptide, not the salt name.

Not FDA-approved — research chemicalWADA (S0) — prohibited in sport at all times

Reviewed by CalcMyPeptide Editorial Team

·Last updated: April 2026·Evidence: Strong preclinical·1 peer-reviewed citation

Typical research dose

250-500 mcg/day (injectable) or vendor oral protocols (salt marketed for GI stability)

Frequency

1-2× daily

Half-life

Not published for the salt; BPC IV PK is minutes

Common vials

5 mg / 10 mg

CAS

N/A (salt)

Molecular weight

~1.4 kDa peptide + arginine

Dose it

5 mg + 2 mL BAC water → 2.5 mg/mL · 250 mcg ≈ 10 units (U-100)

Open in calculator

Mechanism of Action

Pentadeca arginate is BPC-157 as the arginine salt instead of acetate. Sequence is the same pentadecapeptide. Oral-stability claims are formulation marketing. Published animal PK/repair papers are almost entirely BPC-157 acetate/free peptide. FDA Category 2 follows the peptide, not the salt name.

Source: BPC-157: PMID: 29936067, PMID: 30915550. Arginate salt: vendor chemistry, not a separate INN.

Same peptide as BPC-157

If your question is mechanism or Category 2 status, use the BPC-157 leaf. This page exists because vendors sell PDA as a separate SKU (often oral). Do not double-count it as a new INN.

Dosing Protocol

Typical Dose	250-500 mcg/day (injectable) or vendor oral protocols (salt marketed for GI stability)
Frequency	1-2× daily
Half-Life	Minutes (IV PK of BPC-157)* — salt form PK unpublished
Common Vial Sizes	5 mg, 10 mg

Dosing Protocols

Injectable (treat as BPC-157)

Dose

250–500 mcg/day

Frequency

1–2× daily

Note: Same research range as acetate BPC.

Oral SKU

Dose

Vendor-dependent

Frequency

Daily

Note: No consensus human oral bioavailability figure we will print as fact.

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 250–500 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

Weight	Low Dose	Target Dose	High Dose
120 lb(54 kg)	193 mcg	289 mcg	386 mcg
140 lb(63 kg)	225 mcg	338 mcg	450 mcg
160 lb(73 kg)	261 mcg	391 mcg	521 mcg
180 lb(82 kg)	293 mcg	439 mcg	586 mcg
200 lb(91 kg)	325 mcg	488 mcg	650 mcg
220 lb(100 kg)	357 mcg	536 mcg	714 mcg
250 lb(113 kg)	404 mcg	605 mcg	807 mcg

💉 For exact syringe units based on your vial concentration, use the Pentadeca arginate Reconstitution Calculator →

Administration

Route

SC or oral (SKU-dependent)

Timing

As with BPC-157 if injectable.

Fasting Required?

No — food timing not critical

Expected Timeline

As BPC-157

Do not invent a faster oral timeline.

Who Is It For?

BPC-157 salt SKU

Low

Catalog differentiation. Evidence is the parent peptide.

Reconstitution Example

Vial

5 mg

Diluent

2 mL

Concentration

2.5 mg/mL

Per Unit (100u syringe)

25 mcg

Dose of 250 mcg = 10 units on a 100-unit insulin syringe

🧮 Calculate Your Exact Pentadeca arginate Dose →

Safety & Considerations

Same caveats as BPC-157: research-only, Category 2, angiogenic theoretical risk. Salt change is not a safety database.

Regulatory & Legal Status

FDA Status (US)

Research Only

Arginine salt of BPC-157 — same FDA Category 2 peptide, different counterion

WADA Status (2026)

Prohibited (S0)

Competitive athletes subject to anti-doping controls should not use Pentadeca arginate.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.